ICP-538 / InnoCare - LARVOL DELTA

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1 trial

InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China (GlobeNewswire) - "This is the first VAV1 degrader approved to enter clinical trials in China and the second globally....ICP-538 will be developed for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis."

Trial status • Inflammatory Bowel Disease • Multiple Sclerosis • Systemic Lupus Erythematosus

InnoCare Pharma…announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD) (GlobeNewswire) - "This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors, for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis."

New trial • Inflammatory Bowel Disease • Multiple Sclerosis • Systemic Lupus Erythematosus